Teva Pharmaceuticals has received FDA approval for AJOVY (fremanezumab-vfrm) as a preventive treatment for episodic migraines in children and adolescents aged 6–17 who weigh at least 45 kilograms. This makes AJOVY the first and only CGRP antagonist approved for both pediatric episodic migraine prevention and adult migraine treatment. The once-monthly injection can be given in a doctor’s office or at home, giving families more flexibility. Chris Fox, Executive Vice President at Teva, said, ‘This approval gives younger patients a new treatment option, filling a long-standing gap in care and supporting families dealing with this condition.’ Migraines affect about 1 in 10 children and teens in the U.S., often leading to missed school and social disruptions. Despite its commonness, pediatric migraines are often overlooked and undertreated. Dr. Jennifer McVige, a pediatric neurologist, explained, ‘AJOVY provides a targeted way to prevent migraines in younger patients, helping reduce how often they happen.’ AJOVY was first approved in 2018 for adults, and this expansion shows Teva’s commitment to improving migraine treatments for all ages. Migraines cause severe headaches, nausea, and sensitivity to light and sound, which can greatly impact a child’s school performance and emotional health. With this approval, families now have a new way to manage migraines in kids, who have had few treatment options in the past.